Actinium Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 1.4918 USD (Oct 30, 2026, 1:05 PM EDT) · Market cap 46.90M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody...